Curasight Feed

2026-02-09 17:16:00 Curasight: Major Shareholding Notification

2026-01-12 18:00:51 Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT[®] in High-Grade Gliomas 12,50 DKK | +11,61% | 6,21 MDKK

2026-01-05 10:30:11 Curasight to hold Meetings in San Francisco During J.P. Morgan Healthcare Conference Week 11,50 DKK | +10,58% | 1,46 MDKK

2025-12-29 13:18:45 Curasight A/S resolves to issue a convertible loan note 12,15 DKK | -10,00% | 3,08 MDKK

2025-12-29 10:31:46 Curasight: Resolutions of the Extraordinary General Meeting December 2025 12,15 DKK | -10,00% | 3,08 MDKK

2025-12-18 17:19:17 Curasight Announces Successful Dosing of First Patient in Phase 1 trial with uTREAT[®] in Brain Cancer 10,55 DKK | +1,93% | 0,39 MDKK

2025-12-14 17:34:00 Curasight: Notice of Extraordinary General Meeting 9,42 DKK | -5,61% | 0,86 MDKK

2025-12-12 22:37:56 Curasight A/S has successfully completed a directed issue of shares of approximately DKK 16.4 million and has entered into a new loan facility

2025-12-12 18:38:58 Curasight A/S announces its intention to carry out a directed issue of shares and enter into a new loan facility

2025-11-28 11:09:28 Curasight to present at HC Andersen Capital 6,32 DKK | +3,61% | 0,44 MDKK

2025-11-27 07:00:00 Curasight: Interim report Q3 2025 6,10 DKK | -6,15% | 0,79 MDKK

2025-11-26 07:11:27 Curasight's uTREAT® Phase 1 Trial in Brain Cancer Now Open for Patient Enrollment 6,50 DKK | +1,56% | 0,60 MDKK

2025-11-13 08:23:48 Curasight to present at Dansk Aktionærforening InvestorDagen 4,98 DKK | +4,84% | 0,20 MDKK

2025-10-29 08:10:00 Curasight advances Phase 2 uTRACE prostate cancer trial with all European clinical sites in Part 2 now recruiting 4,89 DKK | +1,45% | 0,48 MDKK

2025-10-01 07:00:00 Curasight announces broadening and extension of patent protection for uTRACE® 5,44 DKK | +7,51% | 0,41 MDKK

2025-09-03 21:51:44 Transaction with shares in Curasight A/S made by managerial employee 5,78 DKK | -11,08% | 2,45 MDKK

2025-08-28 07:00:00 Curasight: Half-year report Q2 2025 4,18 DKK | +1,21% | 0,17 MDKK

2025-08-26 07:05:00 Curasight announces acceptance of clinical trial application (CTA) for phase 1 trial with uTREAT[®] in brain cancer patients 4,33 DKK | +11,60% | 0,60 MDKK

2025-06-23 17:35:00 Curasight A/S announces outcome of T03 warrant exercise 2,08 DKK | -8,37% | 0,19 MDKK

2025-06-18 17:35:00 Curasight A/S submits Clinical Trial Application for Phase 1 trial with uTREAT[®] in brain cancer patients 2,24 DKK | +10,89% | 0,48 MDKK

2025-06-03 17:45:00 Curasight: The exercise period commences for warrants of series TO3 on 4 June 2025 2,89 DKK | +9,89% | 0,03 MDKK

2025-06-02 08:15:00 Curasight carries out a directed issue of shares to guarantors in connection with the completed rights issue 2,56 DKK | -30,62% | 0,46 MDKK

2025-05-28 17:25:00 Curasight: Completed registration of rights issue 3,69 DKK | +2,22% | 0,05 MDKK

2025-05-28 14:26:00 Resolutions of the Annual General Meeting 2025 of Curasight A/S 3,69 DKK | +2,22% | 0,05 MDKK

2025-05-21 08:14:00 Curasight announces outcome in rights issue 4,50 DKK | -16,67% | 0,26 MDKK

2025-05-15 16:09:23 Subscription of new shares in the Right Issue 2025 exercised by Curasight management 2,55 DKK | +10,87% | 0,02 MDKK

2025-05-13 17:14:00 Curasight: Notice of Annual General Meeting 2025 2,10 DKK | -5,83% | 0,06 MDKK

2025-05-13 08:46:30 Last day of the subscription period in Curasight's rights issue of shares 2,10 DKK | -5,83% | 0,06 MDKK

2025-05-07 08:06:12 Curasight A/S selects CRO to run Phase 1 trial with uTREAT[®] in brain cancer 2,13 DKK | 0,00% | 0,02 MDKK

2025-05-02 07:30:53 Curasight: THE SUBSCRIPTION PERIOD IN CURASIGHT'S RIGHTS ISSUE OF SHARES BEGINS TODAY 2,27 DKK | -9,92% | 0,20 MDKK

2025-04-30 12:17:43 Curasight to present at HC Andersen Capital 2,94 DKK | +2,40% | 0,11 MDKK

2025-04-29 22:22:09 Curasight A/S publishes disclosure document regarding rights issue 2,94 DKK | +2,40% | 0,11 MDKK

2025-04-25 08:47:08 Curasight: Annual Report for the fiscal year 2024 3,33 DKK | +21,09% | 0,16 MDKK

2025-04-25 08:25:07 Curasight: Interim report Q1 2025 3,33 DKK | +21,09% | 0,16 MDKK

2025-04-24 08:30:33 Curasight: CURASIGHT A/S ANNOUNCES FINAL TERMS OF RIGHTS ISSUE 2,75 DKK | -14,46% | 0,20 MDKK

2025-04-23 11:38:15 Resolutions of the Extraordinary General Meeting of Curasight A/S on 23 April 2025 3,22 DKK | +4,09% | 0,07 MDKK

2025-04-08 20:42:48 Notice of Extraordinary General Meeting of Curasight A/S 3,53 DKK | -12,29% | 0,05 MDKK

2025-04-04 17:14:00 Curasight A/S resolves on its intention to carry out a rights issue of shares of approximately DKK 100 million 4,23 DKK | -6,60% | 0,05 MDKK

2025-03-26 07:00:00 Curasight announces new date of the Annual General Meeting and an updated financial calendar 2025 4,58 DKK | -4,09% | 0,01 MDKK

2025-02-27 07:00:00 Curasight: Year-end report Q4 2024

2025-02-05 09:24:50 Curasight announces an updated financial calendar 2025 5,16 DKK | -7,04% | 0,00 MDKK

2024-12-10 19:05:17 Participation in warrant exercise by Curasight management 6,32 DKK | +7,84% | 0,09 MDKK

2024-12-10 07:22:00 Curasight A/S announces outcome of warrant exercise 5,86 DKK | -6,85% | 0,42 MDKK

2024-12-02 08:10:00 Curasight: SEB maintain valuation range midpoint at DKK 54 per share 6,49 DKK | +1,35% | 0,45 MDKK

2024-12-02 07:00:00 Curasight: The last day of trading in warrants of series TO2 is on the 3[rd] of December 2024 6,49 DKK | +1,35% | 0,45 MDKK

2024-11-22 08:25:06 Curasight and Curium sign global radioisotope supply agreement for uTREAT[®] 6,26 DKK | -5,22% | 0,04 MDKK

2024-11-21 07:55:00 Curasight: The exercise period for warrants of series TO2 commences today 6,60 DKK | -3,36% | 0,10 MDKK

2024-11-21 07:00:00 Curasight: Interim report Q3 2024 6,60 DKK | -3,36% | 0,10 MDKK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Curasight

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden